Clinical Trials Logo

Clinical Trial Summary

The overall objective of this study is to determine the feasibility and tolerability of single dose Intraoperative Electron Radiation Treatment ("IOERT") as definitive therapy when administered at the time of breast conserving surgery for patients with early stage breast cancer.


Clinical Trial Description

Evaluate local and distant recurrence rates and cosmetic outcomes. Both clinical evaluation of cosmetic outcome by the Surgeon, and subjective impression of cosmetic outcome by the patient, are evaluated using questionnaire.

Local recurrence is evaluated under the same imaging protocol used for Whole breast radiation. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01960803
Study type Interventional
Source Advocate Health Care
Contact
Status Completed
Phase N/A
Start date May 1, 2013
Completion date July 1, 2019

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02221999 - Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients Phase 2/Phase 3
Recruiting NCT03749850 - Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer Phase 1
Completed NCT01583426 - Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) Phase 3
Recruiting NCT02879513 - Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy Phase 3
Completed NCT02199418 - Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer Phase 2
Completed NCT02682693 - Denosumab as an add-on Neoadjuvant Treatment (GeparX) Phase 2
Completed NCT02125344 - A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) Phase 3
Completed NCT01426880 - Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer Phase 2/Phase 3